Illumina Sees Decline in Core Segment Sales Due to Biotech Funding Crunch

Tuesday, 6 August 2024, 22:54

Illumina is facing a **decline in core revenue** as demand for its tools and services drops due to a challenging funding environment for biotechnology companies. Key markets, particularly **China**, are exhibiting sluggish demand while instrument sales are impacted by high interest rates. Although **consumable sales have remained stable**, the company anticipates a **2% to 3% decrease in Core Illumina revenue** compared to the prior year. This trend highlights the ongoing challenges in the biotech sector and its effects on associated technology providers.
Yahoo Finance
Illumina Sees Decline in Core Segment Sales Due to Biotech Funding Crunch

Illumina's Sales Forecast

Illumina has recently announced expectations for a decline in full-year sales from its core segment, largely attributed to a growing funding crunch in the biotechnology sector.

Key Insights

  • The company observes sluggish demand for its tools used in developing therapies and vaccines.
  • Key markets like China are indicating a decrease in demand.
  • Customers, particularly biotechnology firms, show caution in spending due to highinterest rates.

Sales Performance

According to CEO Jacob Thaysen, consumable sales have remained solid as customers continue to increase their sequencing activity. However, demand for instruments has softened significantly.

Future Projections

Illumina anticipates its Core Illumina revenue could decline by 2% to 3% compared to the previous fiscal year, reflecting the broader challenges faced by the biotech industry.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most reliable and up-to-date tech news. Stay informed and elevate your tech expertise effortlessly.

Subscribe